Treatment
Cell clinical trials
We’re tracking 5,723 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07300683RecruitingPhase 1
Modified immune cells for T-cell leukemia/lymphoma
This trial tests a new type of immunotherapy called anti-CCR9 CAR T cells for people whose T-cell leukemia or lymphoma has not responded to standard chemotherapy. The treatment uses your own immune cells that are modified in a lab to find and attack cancer cells that have a specific marker (CCR9) on their surface.
LondonAges Any age - NCT07478848RecruitingPhase 1
Radiation, Vancomycin, and CAR-T for B-cell lymphoma
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT03375619Recruiting
Long-term follow-up after CAR-T treatment
This study checks in with people who already received CAR-T therapy to learn how they’re doing over time. It may help doctors understand the long-term benefits and side effects of CAR-T for future patients.
Milwaukee, WisconsinAges 18–80 - NCT07413978RecruitingPhase 1/Phase 2
Stem cell injection for severe ARDS
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
Wuhan, HubeiAges 18–80 - NCT07428044RecruitingPhase 2
Trastuzumab Deruxtecan for HER2-mutant lung cancer before surgery
This trial tests a targeted drug, trastuzumab deruxtecan, for people with non-small cell lung cancer that has a specific HER2 gene change. The treatment is given before surgery to shrink the tumor and make it easier to remove.
Ann Arbor, MichiganAges 18 years+ - NCT07517198RecruitingPhase 1
EXS74539 Study for Advanced Solid Tumors
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+ - NCT07563205Recruiting
Study of Chemotherapy and Amivantamab for Advanced Lung Cancer
This study follows patients with advanced lung cancer (a type called non-small cell lung cancer) who are receiving a combination of chemotherapy and a drug called amivantamab. Researchers want to understand how well this treatment works and track your health outcomes over time.
Aix-en-ProvenceAges 18 years+ - NCT07311070Enrolling by invitationPhase 3
Methylene blue gel for skin cancer not treated by surgery or radiation
This trial tests a methylene blue gel for people with certain types of basal cell carcinoma (a common skin cancer) who cannot have surgery or radiation. The goal is to see if the gel can treat the cancer safely and effectively.
Mashhad, Razavi Khorasan ProvinceAges 18 years+ - NCT07187778RecruitingPhase 2
Kidney cancer treatment before surgery
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Houston, TexasAges 18 years+ - NCT06227026RecruitingPhase 1
CAR-T cell therapy for blood cancers that came back
This trial tests a type of immunotherapy called CAR-T cells, which are your own immune cells modified to attack cancer. It is for adults with certain blood cancers (like lymphoma or leukemia) that have not responded to at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT07623369RecruitingPhase 1
First-in-Human Study of HH160 for Advanced Solid Tumors
This is an early-stage trial testing a new drug called HH160 in patients with advanced cancer (solid tumors). Researchers want to find the right dose and learn how well it works and what side effects it causes.
Waratah, New South WalesAges 18–75 - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Birmingham, AlabamaAges 18 years+ - NCT07282210RecruitingPhase 2
New medicine for sickle cell hemolysis
This trial tests a new medicine (SIL-8301) to help control red blood cell breakdown (hemolysis) in people with sickle cell disease. It is for those who are already taking hydroxyurea and have had few pain crises but still have complications from hemolysis.
Toronto, OntarioAges 16–35 - NCT07172958RecruitingPhase 1
Immune cell therapy for children with certain solid tumors
This trial tests a new type of immune cell therapy called CAR T cells that are designed to recognize and attack cancer cells in children and young adults with certain solid tumors that have come back or not responded to standard treatment.
Washington D.C., District of ColumbiaAges 1–23 - NCT06980116RecruitingPhase 1
Finding the right dose of EXS73565 for relapsed B-cell cancers
This study tests a new oral medication (EXS73565) for people with B-cell blood cancers that came back or didn't respond to standard treatments. It aims to find the best dose and check if it's safe and helpful.
TbilisiAges 18 years+ - NCT07155200RecruitingPhase 1/Phase 2
Study of a new drug combined with irinotecan for small cell lung cancer
This study tests a new drug (cirtuvivint) combined with irinotecan, a common chemotherapy, for people whose small cell lung cancer has progressed after at least one prior treatment. The goal is to see if the combination helps control the cancer and whether it is safe.
St Louis, MissouriAges 18 years+ - NCT07191249RecruitingPhase 2
Mosunetuzumab for low-tumor-burden follicular lymphoma
This trial tests a new drug, mosunetuzumab, given as a shot under the skin for people with a slow-growing type of lymphoma (follicular lymphoma) that has not yet been treated and is not causing heavy symptoms or large tumor masses.
HaifaAges 18 years+ - NCT07341191RecruitingPhase 2
Sonrotoclax and zanubrutinib before CAR-T for mantle cell lymphoma
This trial tests a combination of two targeted drugs (sonrotoclax and zanubrutinib) given before your planned CAR-T cell therapy. The goal is to see if this approach can help control the lymphoma while you wait for CAR-T.
Edmonton, AlbertaAges 18 years+ - NCT07187869RecruitingPhase 1
Cabozantinib plus nivolumab for kidney cancer with bone spread
This study tests whether adding a drug called cabozantinib to standard nivolumab treatment helps fight kidney cancer that has spread to bone. It aims to understand how the bone environment changes during treatment.
Houston, TexasAges 18 years+ - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
Chicago, IllinoisAges 18–80 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,723 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.